araag2/HINT huggingface dataset:
Clinical trial NCT00524849 (phase 2/phase 3, status: completed)
Conditions: metastatic breast cancer, bone metastases
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: zoledronic acid
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Female, 18 years or older

          -  Histologically confirmed invasive breast cancer

          -  Bone metastases

          -  ECOG Performance Status of 0 to 2

          -  Life expectancy of more than 3 months

          -  Subject must have adequate organ function:

               -  Cr ≤ 3 mg/dL (265 µmol/L)，

               -  CrCl (Cockcroft & Gault) ≥ 30 mL/min，

               -  Ca2+ > 8.0 mg/dL (2.0 mmol/L) and ≤ 12 mg/dL (3.0 mmol/L)

          -  Negative serum pregnancy test for women with childbearing potential

          -  Good conditions for infusion and willing to undergo phlebotomy during the whole study

          -  Have ceased anti-tumor treatment including chemotherapy, endocrinotherapy and
             bio-targeted therapy for over 28 days

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  History of other malignancy. However, subjects who have been disease-free for 5 years,
             or subjects with a history of completely resected non-melanoma skin cancer or
             successfully treated in situ carcinoma are eligible.

          -  Concurrent disease or condition that would make the subject inappropriate for study
             participation, or any serious medical disorder that would interfere with the subject's
             safety

          -  Active or uncontrolled infection

          -  Current active dental problems including infection of the teeth or jawbone (maxilla or
             mandible); dental or fixture trauma; or a current or prior diagnosis of osteonecrosis
             of the jaw (ONJ); or exposed bone in the mouth; or slow healing after dental
             procedures

          -  Recent (within 6 weeks of Randomization) or planned dental or jaw surgery (e.g.
             extraction, implants)

          -  Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart
             failure

          -  Concomitant with liver, brain or symptomatic lung metastases (symptoms such as
             hemoptysis, severe cough and shortness of breath)

          -  Accepted radiotherapy for solitary bone disease within 30 days before study

          -  Previous treatment with other bisphosphonates or radionuclides within one month before
             study

          -  Known hypersensitivity to bisphosphonates

          -  History of treatment with calcitonin, gallium nitrate or mithracin within 14 days
             before study.
Clinical trial NCT00003850 (phase 2, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: thalidomide
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven squamous cell carcinoma of the head and neck

          -  Recurrent disease OR metastatic disease at initial diagnosis or at recurrence

          -  Initial therapy of surgery and/or radiotherapy, induction chemotherapy, or concurrent
             chemotherapy and radiotherapy allowed

          -  No more than one prior regimen of chemotherapy or biologic therapy for metastatic
             disease

          -  Recurrence after adjuvant or induction chemotherapy may have received one additional
             course of chemotherapy or biologic therapy

        PATIENT CHARACTERISTICS:

          -  Age: 18 and over

          -  Performance status: Zubrod 0-2

          -  Life expectancy: At least 3 months

          -  WBC at least 3000/mm3

          -  Platelet count at least 100,000/mm3

          -  Hematocrit at least 30%

          -  Bilirubin no greater than 1.5 times normal

          -  SGOT/SGPT no greater than 1.5 times normal

          -  Creatinine no greater than 1.5 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile women must use 2 methods of effective contraception, 1 barrier and 1 hormonal,
             beginning at least 4 weeks before study and continuing during and for 1 month after
             study

          -  Men must use effective barrier contraception during and for 1 month after study

          -  No grade 2 or greater peripheral neuropathy

          -  No serious infection or other concurrent illness requiring immediate therapy

          -  Must be able to take oral medications

          -  No medical or social factors that would interfere with compliance

        PRIOR CONCURRENT THERAPY:

          -  Any number of courses of one regimen of chemotherapy allowed

          -  No concurrent cytotoxic chemotherapy

          -  No concurrent radiotherapy
Clinical trial NCT01039701 (phase 2, status: completed)
Conditions: mild to moderate alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: azd1446, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  history of progressive worsening of memory and other cognitive functions for at least
             12 months

          -  treatment with stable dose of donepezil (10 mg) for at least 3 months

          -  the patient should have an appropriate caregiver, who is required for all study visits

        Exclusion Criteria:

          -  history of allergy/hypersensitivity reactions

          -  significant neurological disease or dementia other than Alzheimer's disease

          -  myocardial infarction or acute coronary syndrome within the last year
Clinical trial NCT00541112 (phase 2, status: terminated)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, fluorouracil, leucovorin calcium, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    toxicity and lack of efficacy
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the rectum

               -  Locally advanced (T3-4 Nx) or metastatic (T2 N+ M1) synchronous disease

                    -  Metastases must be resectable

               -  Primary tumor examined by endorectal echography and MRI

          -  Measurable disease by thoraco-abdomino-pelvic scanner

          -  Disease considered susceptible to treatment with radiotherapy and chemotherapy

          -  No diffuse metastases considered nonresectable

          -  No acute occlusion not caused by colostomy

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG performance status 0-2

          -  WBC ≥ 4,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10 g/dL

          -  Creatinine ≤ 130 µmol/L

          -  Transaminases ≤ 5 times upper limit of normal (ULN)

          -  Total bilirubin ≤ 1.5 times ULN

          -  Alkaline phosphatase ≤ 2.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients of must use effective contraception

        Exclusion criteria:

          -  Contraindication to therapy with capecitabine, oxaliplatin, cetuximab, and/or
             radiotherapy

          -  Impossible to perform translational analyses

          -  Uncontrolled severe illness

          -  Severe renal or hepatic insufficiency

          -  Cardiac insufficiency or symptomatic coronary disease

          -  Sensitive peripheral neuropathy

          -  Uncontrolled diabetes

          -  Other malignancy within the past 10 years except previously treated basal cell skin
             cancer or carcinoma in situ of the cervix

          -  Impossible to participate in study due to geographic, social, or psychiatric reasons

          -  Patients who are under supervision or incarcerated

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior anticancer chemotherapy or radiotherapy for this cancer

          -  No therapy with coumarin anticoagulants, phenytoin, sorivudine, brivudine, antacids,
             or allopurinol

          -  No concurrent participation in another therapeutic study or receiving another
             experimental drug
Clinical trial NCT00569946 (phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: ag-013736
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients histologically diagnosed as metastatic renal cell cancer with a component of
             clear cell cancer.

          -  Patients who are refractory to cytokine therapy as 1st line.

          -  Patients who experienced nephrectomy.

          -  Patients with at least 1 target lesion, as defined by RECIST.

          -  Patients with no uncontrolled hypertension.

        Exclusion Criteria:

          -  Gastrointestinal abnormalities

          -  Current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2/3A4
             inducers.

          -  Active seizure disorder or evidence of brain metastases.

          -  Patients with hemoptysis.
Clinical trial NCT00679510 (phase 2/phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: rosuvastatin, placebo
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients will be selected from a high risk population of hospital clinic attendees,
             defined as RA greater than 5 years' disease duration, and all will be RA latex
             seropositive or IgM RF ELISA >14iu/ml. The subjects will be of either sex and >40
             years of age.

          -  Patients should have both tender and swollen joint counts >4 each and either a CRP
             >10mg/l, ESR >25mm/h or PV >1.78.

          -  Patients on cyclosporine or other medications known to be contraindicated with this
             form of drug will not be enrolled.

        Exclusion Criteria:

          -  The patient's hospital and general practice records will be scrutinised for evidence
             of symptomatic vascular disease.

          -  Any patient not free from vascular disease symptoms will be excluded.

          -  In addition to evidence of symptomatic vascular disease (either previous or current),
             the exclusion criteria consist also of those already taking lipid-lowering therapy or
             those with contraindications to these therapies.

          -  Also excluded will be subjects with a total cholesterol level of >7.5mmol/L as it
             might be argued that such patients merit primary prevention on the basis of
             dyslipidemia alone.
Clinical trial NCT00568451 (phase 2, status: terminated)
Conditions: melanoma (skin)
ICD codes: C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, D03.52
Drugs: carboplatin, paclitaxel, temozolomide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CSCC[C@H](N)C(O)=O
Reason stopped: 
    slow accrual.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed metastatic melanoma

               -  Stage IV disease

               -  Progressive disease

               -  No known standard therapy that is potentially curative or proven capable of
                  extending life expectancy exists

          -  Planning to undergo chemotherapy with paclitaxel and carboplatin OR temozolomide alone
             for progressive disease

          -  Measurable disease as defined by RECIST criteria

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 3 months

          -  ANC ≥ 1,500/mL

          -  Platelet count ≥ 100,000/mL

          -  Hemoglobin ≥ 9 g/dL

          -  Creatinine ≤ 2.5 x upper limit of normal (ULN)

          -  AST ≤ 3 x ULN

          -  Alkaline phosphatase ≤ 3.0 x ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 1 month after
             completion of study therapy

          -  No uncontrolled intercurrent illness including, but not limited to, any of the
             following:

               -  Active infection

               -  NYHA class III or IV congestive heart failure

          -  No history of other malignancy within the past 5 years except for basal cell or
             squamous cell carcinoma of the skin treated with local resection only or carcinoma in
             situ of the cervix

          -  Willing to provide research blood samples

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from prior therapy

          -  At least 4 weeks since prior radiotherapy

          -  At least 4 weeks since prior chemotherapy (patients who received chemotherapy in the
             metastatic setting)

               -  No prior chemotherapy treatment with agents similar to study drugs

          -  No prior chemotherapy in the metastatic setting (for chemo-naive patients)

          -  No concurrent enrollment in a different clinical study in which investigational
             procedures or agents are being used

          -  No other concurrent investigational agents

          -  No other concurrent chemotherapy or radiotherapy, including palliative radiotherapy
Clinical trial NCT01562743 (phase 2, status: completed)
Conditions: idiopathic restless legs syndrome
ICD codes: E20.0, I95.0, L50.1, D61.3, G24.2, G24.4, G60.3
Drugs: spm 962
SMILES: CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject completed the preceding trial 243-07-003 (NCT00666965)

        Exclusion Criteria:

          -  Subject discontinued from the preceding trial 243-07-003 (NCT00666965)

          -  Subject had a serious adverse event which association with the investigational drug is
             not ruled out during trial 243-07-003

          -  Subject had a persistent serious adverse event at the baseline, which was observed and
             association with the investigational drug is ruled out during trial 243-07-003.

          -  Subject had persistent hallucination or delusion during trial 243-07-003.

          -  Subject had psychiatric conditions such as confusion, excitation, delirium, abnormal
             behaviour at the baseline.

          -  Subject had orthostatic hypotension or a systolic blood pressure (SBP) ≤ 100 mmHg and
             had a decrease of SBP from spine to standing position ≥ 30 mmHg at baseline.

          -  Subject had a history of epilepsy, convulsion etc. during trial 243-07-003.

          -  Subject developed serious ECG abnormality at the baseline.

          -  Subject had QTc-interval ≥ 500 msec at the baseline or subject had an increase of
             QTc-interval ≥ 60 msec from the baseline in the trial 243-07-003 and had a
             QTc-interval > 470 msec in female or > 450 msec in male at the baseline.

          -  Subject had a serum potassium level < 3.5 mEq/L at the end of the taper period in
             trial 243-07-003.

          -  Subject had a total bilirubin ≥ 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5
             times of the upper limit of the reference range (or ≥ 100 IU/L) at the end of the
             period in trial 243-07-003.

          -  Subject had BUN ≥ 30 mg/dL or serum creatinine ≥ 2.0 mg/dl at the end of the taper
             period in trial 243-07-003.

          -  Subject who planned pregnancy during the trial.

          -  Subject was judged to be inappropriate for this trial by the investigator for the
             reasons other than above.
Clinical trial NCT00112489 (phase 2, status: completed)
Conditions: sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: carboplatin, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed uterine carcinosarcoma (mixed mesodermal tumor)

               -  Stage III or IV disease

               -  Persistent or recurrent disease

          -  Documented disease progression

          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
             conventional techniques OR ≥ 10 mm by spiral CT scan

               -  At least 1 target lesion

                    -  Tumors within a previously irradiated field are not considered target
                       lesions unless there is documented disease progression

          -  Ineligible for any higher priority Gynecology Oncology Group (GOG) protocol (i.e., any
             active GOG phase III protocol for the same patient population)

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  GOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Platelet count ≥ 100,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  SGOT ≤ 2.5 times ULN

          -  Alkaline phosphatase ≤ 2.5 times ULN

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active infection requiring antibiotics

          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

          -  No sensory or motor neuropathy > grade 1

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior cytotoxic chemotherapy for uterine sarcoma

        Endocrine therapy

          -  At least 1 week since prior hormonal therapy for uterine sarcoma

          -  Concurrent hormone replacement therapy allowed

        Radiotherapy

          -  See Disease Characteristics

        Surgery

          -  Not specified

        Other

          -  Recovered from all prior therapy

          -  No prior anticancer therapy that would preclude study therapy
Clinical trial NCT00264498 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: gefitinib, gemcitabine, carboplatin
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced Non Small cell Lung Cell Lung cancer

          -  Never received chemotherapy

          -  Up and about 50% of waking hours

        Exclusion Criteria:

          -  Spread of lung cancer to the brain

          -  Low level of white blood cells

          -  Radiotherapy within 4 weeks

        Patients were entered to this study, initiated in 2004, before the significance of
        predictive factors such as smoking history, adenocarcinoma histology and mutation status
        was described.
Clinical trial NCT03064113 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease, copd
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: placebo, td-4208 700 μg, td-4208 350 μg, ipratropium 500 μg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1, CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1, [H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of moderate stable Chronic Obstructive Pulmonary.

          -  Disease with FEV1/FVC <0.7 at screening.

          -  Woman of non-childbearing potential.

          -  Female participants of childbearing potential must test negative for pregnancy and
             must be using a highly effective method of birth control during the study and for at
             least 1 month after completion of study dosing.

          -  Female participants must not be breastfeeding.

          -  Men must agree to use a highly effective method of birth control with partners of
             childbearing potential during the study and for 1 month after completion of study
             dosing.

          -  Current or past smoking history >10 pack-years.

          -  Must be capable of performing reproducible spirometry maneuvers.

        Exclusion Criteria:

          -  History of significant respiratory disease other than COPD, and/ or requires daily
             long-term oxygen therapy.

          -  Exacerbation of COPD, lung infection within 6 weeks prior to study.

          -  Start of or change in dose of COPD treatment 4 weeks before study.

          -  Daily using of maintenance systemic/inhaled corticosteroids (>1000 microgram of
             fluticasone propionate equivalent or >5 mg prednisone).

          -  Use of bronchodilators or medication for the treatment of COPD, aspirin,
             anti-inflammatories for a specific time, prior to the first dose or is not willing to
             abstain from their use for the specified time periods prior to study dose
             administration.

          -  Symptomatic prostrate hypertrophy, bladder neck obstruction, active cancer, narrow
             angle glaucoma.

          -  Clinical significant hypersensitivity to medications.

          -  Participants have an uncontrolled hematologic, immunologic, renal, neurologic,
             hepatic, endocrine or other disease that may place participant at risk.

          -  Cerebrovascular, cardiovascular disease or abnormal ECG.

          -  History of drug or alcohol abuse.